Brief: Rain Oncology To Be Acquired By Pathos AI For $1.16 In Cash Per Share Plus Contingent Value Rights
13/12/2023 23:26
Dec 13 (Reuters) - Rain Oncology Inc RAIN.O :
* RAIN ONCOLOGY ENTERS INTO AGREEMENT TO BE ACQUIRED BY
PATHOS AI
FOR $1.16 IN CASH PER SHARE PLUS CONTINGENT VALUE RIGHTS
* RAIN ONCOLOGY INC- RAIN BOARD OF DIRECTORS VOTED
UNANIMOUSLY TO
APPROVE PROPOSED OFFER
* RAIN ONCOLOGY INC- PATHOS HAS ESTABLISHED A SEPARATE,
WHOLLY-OWNED SUBSIDIARY TO COMPLETE TRANSACTION
* RAIN ONCOLOGY INC- FOLLOWING TENDER OFFER CLOSING, PATHOS
UNIT
WILL BE MERGED INTO RAIN WITH RAIN AS SURVIVING ENTITY OF MERGER
Source text for Eikon: ID:nGNXbkV9P4
Further company coverage: RAIN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Rain Oncology
See all newsBrief: Rain Enhancement Technologies Holdco - May Offer Up To $25 Million In Securities From Time To Time - SEC Filing
Brief: Rain Enhancement Technologies Holdco Inc - Q1 And Q2 2025 Financial Statements Should Not Be Relied Upon Due To Accounting Error - SEC Filing
Brief: Rain Oncology Pursuant To Proposed Deal With Pathos AI
Brief: Rain Oncology To Be Acquired By Pathos AI For $1.16 In Cash Per Share Plus Contingent Value Rights
Brief: Rain Oncology Q3 Net Income USD -7.034 Million